India’s Zydus Lifesciences and its U.S. unit will pay $120 million to Astellas Pharma as part of a deal to settle a patent dispute over the Japanese drugmaker’s bladder disorder drug Mirabegron, the Indian firm said on Thursday.
India’s Zydus Lifesciences and its U.S. unit will pay $120 million to Astellas Pharma as part of a deal to settle a patent dispute over the Japanese drugmaker’s bladder disorder drug Mirabegron, the Indian firm said on Thursday.